The location of locoregional recurrence in pathologic T3N0, non-irradiated lower rectal cancer by 湲덇린李� et al.
97Copyright © 2013.  The Korean Society for Radiation Oncology
The location of locoregional recurrence in pathologic 
T3N0, non-irradiated lower rectal cancer
Mi Sun Kim, MD1, Ki Chang Keum, MD1, Woo Joong Rhee, MD1, Hyunju Kim, MD1, Minji Kim, MD1, 
Seohee Choi, MD1, Ki Chang Nam, PhD2, Woong Sub Koom, MD1
Departments of 1Radiation Oncology and 2Medical Engineering, Yonsei University College of Medicine, Seoul, Korea
Radiat Oncol J 2013;31(2):97-103
http://dx.doi.org/10.3857/roj.2013.31.2.97
pISSN 2234-1900 · eISSN 2234-3156  
Original Article
Purpose: To investigate the patterns of locoregional recurrence of pathologic T3N0 (pT3N0) lower rectal cancer omitting 
postoperative radiotherapy (RT) and explore the potential of modification of a RT field. 
Materials and Methods: From Jan 2003 to Nov 2011, 35 patients omitting preoperative or postoperative RT for pT3N0 
lower rectal cancer were included. We defined the lower rectal cancer as the tumor with the inferior margin located below the 
virtual line-a convergent level between rectal wall and levator ani muscle. All patients had radiologic examinations for recurrence 
evaluation during the follow-up duration.
Results: The median follow-up duration was 66.4 months (range, 1.4 to 126.1 months). Eight (22.9%) of the 35 patients had 
recurrence. Three (8.6%) was local recurrence (LR) only, 3 (8.6%) was distant metastasis (DM) only, and 2 (5.7%) was LR with DM. 
All LR were located at primary tumor sites. The overall survival rate, LR-free survival rate, and DM-free survival rate at 5 years was 
79.8%, 83%, and 87%, respectively. All LR developed from tumors over 5 cm. However, there was no statistical significance (p = 
0.065). There was no other risk factor for LR.
Conclusion: Even though the patients included in this study had pathologically favorable pT3N0 rectal cancer, LR developed 
in 14.3% of patients. Most of the LR was located at primary tumor sites prior to surgery. Based on these findings, it might seem 
reasonable to consider postoperative RT with a smaller radiation field to the primary tumor site rather than the conventional whole 
pelvic irradiation.
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Introduction
The Dutch colorectal cancer group showed the benefits of 
preoperative short course radiotherapy for the local control 
of rectal cancer [1]. Also, phase III studies such as the German 
Rectal Cancer Group trial and National Surgical Adjuvant 
Breast and Bowel Project (NSABP) R-03 trial reported that 
preoperative concurrent chemoradiotherapy (CCRT) could 
reduce the pelvic recurrence better than postoperative CCRT 
[2,3]. After these trials, there was a shift of paradigm from 
the postoperative to preoperative CCRT for rectal cancer. 
The current standard of treatment for locally advanced 
rectal cancer is preoperative CCRT followed by surgery and 
postoperative chemotherapy. However, most of these trials 
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included the patients with heterogeneous stage II/III rectal 
cancer and could not find a benefit from the CCRT for specific 
subgroups. 
Gunderson et al. [4] separated the patients with rectal cancer 
into three risk groups on the basis of differential relapse 
and survival rates. Reports indicated that the patients with 
T3N0 rectal cancer had intermediate risk: relatively lower 
relapse rate and higher survival rate and the postoperative 
chemoradiotherapy (CRT) after curative resection could not 
improve the clinical outcome for patients with intermediate 
risk of rectal cancer. The National Comprehensive Cancer 
Network (NCCN) guidelines, however, still recommend the 
preoperative CRT for the patients with cT3N0 rectal cancer. 
Recently, with the advanced diagnostic radiologic technique, 
the accuracy increment of prediction of pathologic T stage 
using magnetic resonance imaging (MRI) and endorectal 
ultrasonography has been achieved. Some of the surgeons 
conduct surgery first on the basis of radiologic findings in 
cT3N0, and do not follow the NCCN guidelines. According to 
the European Society of Medical Oncology (ESMO) guidelines, 
cT1-2 and cT3 rectal cancer with perirectal tissue invasion 
<1–5 mm on the MRI and with negative circumferential 
resection margin (CRM) can be undertaken by surgery first [5]. 
After the curative resection without any neoadjuvant 
treatment, we can consider chemotherapy alone for patients 
with proximal pT3N0 rectal cancer with negative margins 
and favorable pathologic features. Except in these patients, 
adjuvant radiation therapy (RT) is still recommended. Since 
the total mesorectal excision (TME) has been widely used, 
both local control and disease specific survival have been 
improved. Some surgeons believe that surgery alone is enough 
to treat the intermediate risk of rectal cancer in the era of 
standardized TME. The reasons for omitting RT are to get a 
more precise pathologic stage, to avoid over-treatment, to 
reduce RT-induced complications, and to preserve the quality 
of life. The information of RT-induced toxicities is on the basis 
of the European studies that compared preoperative RT and 
TME. They reported more late toxicities like bowel and sexual 
dysfunctions after RT compared with TME alone [6]. If the 
fibrosis of normal tissue and the damage of blood vessels 
and nerves can be decreased by reducing the RT volume, RT-
induced complications can also be decreased. 
Overall, we could not demonstrate the role of postoperative 
RT in pT3No rectal cancer with this study. The aim of this study 
was to investigate the patterns of locoregional recurrence 
(LRR) in patients with pT3N0 lower rectal cancer omitting 
postoperative RT. We focused on the location of local failure in 
order to explore the potential of modification of postoperative 
RT target volume.
Materials and Methods
1. Patients
From Jan 2003 to Nov 2011, a total of 673 patients who had 
undergone surgery for pT3N0 rectal cancer were identified. 
Of them, 182 patients received preoperative RT or CRT and 
299 patients received postoperative RT or CRT. Postoperative 
RT was omitted in 192 patients. Of 192 patients, 35 patients 
who had omitted preoperative or postoperative RT for pT3N0 
lower rectal cancer were included. All patients had computed 
tomography (CT) or MRI preoperatively. Medical records, 
radiological images, and radiological reports of these patients 
were reviewed. All the patients included in this study received 
R0 resection. Surgeons were well trained in TME technique and 
applied the technique to the patients in this study. Omission of 
postoperative RT was determined by the surgeon’s preference. 
Among the 35 patients, 25 patients (71.4%) received adjuvant 
chemotherapy. 
2. Definition of primary tumor location
Primary tumor location was determined by inferior tumor 
margin based on the virtual line (VL). The VL was a convergent 
level between rectal wall and levator ani muscle. If the inferior 
margin of tumor was located below the VL, it was defined as a 
lower rectal tumor (Fig. 1).
3. Evaluation of recurrence
All patients had radiologic examinations for recurrence 
evaluation during the follow-up duration and were followed 
by a serial clinical examination and carcinoembryonic antigen 
assessment. Recurrent tumor that could not be explained by 
normal or postoperative changes at anastomotic sites and 
regional metastatic lymph node recurrence documented 
by colonoscopic, radiologic, or pathologic examination was 
defined as local recurrence (LR). Recurrent disease in any other 
location was defined as distant metastasis (DM). Calculation of 
LR included patients who developed LR only and patients who 
developed both LR and DM. Cumulative events of LRs were 
counted. Overall recurrence was considered when patients 
developed either LR or DM. In case of recurrence, radiologic 
99
LRR in pT3N0 rectal cancer
www.e-roj.orghttp://dx.doi.org/10.3857/roj.2013.31.2.97
examinations were compared with initial preoperative CT or 
MRI to evaluate recurrent tumor locations.
4. Statistical analysis
SPSS ver. 20 (IBM, Armonk, NY, USA) was used for statistical 
analyses. The univariate influence of prognostic factors on 
LR, recurrence-free survival, and overall survival was analyzed 
with the Kaplan-Meier method. The p-values < 0.05 were con-
sidered statistically significant.
Results
1. Clinical and pathological characteristics
A total of 35 patients were included. Patient and tumor 
characteristics are listed in Table 1. The median follow-up 
duration was 66.4 months (range, 1.4 to 126.1 months). The 
follow-up duration in 32 patients (91.4%) was over 2 years. 
Median age was 65 years (range, 27 to 81 years). Median 
preoperative carcinoembryonic antigen (CEA) was 2.8 ng/
mL (range, 0.0 to 35.0 ng/mL) and median postoperative day 
7 CEA was 1.3 ng/mL (range, 0.0 to 11.9 ng/mL). Twenty-two 
patients (62.9%) had undergone lower anterior resection. 
Abdominoperineal resection (APR) and Hartmann’s operation 
was performed in 34.3% and 2.9%, respectively. The median 
number of dissected lymph node was 18 (range, 6 to 45). In 
8 patients (22.9%), the number of dissected lymph nodes 
was under 12. All operations for included patients were R0 
resection. Median resection margin (RM) was 1.5 cm (range, 0.1 
to 15.0 cm) in distal, 12 cm (range, 2.5 to 30.0 cm) in proximal, 
and 0.6 cm (range, 0.1 to 1.3 cm) in circumferential. There was 
13 patients with close RM; 10 patients with distal RM < 1 cm; 
3 patients with CRM < 0.2 cm. Of them, 9 patients received 
postoperative chemotherapy. Among the 4 patients who did 
not receive postoperative chemotherapy, 1 patient refused 
adjuvant treatment and others did not received adjuvant 
treatment by surgeon’s opinion. Median tumor size was 5 cm 
(range, 2.5 to 9.0 cm). Poorly differentiated adenocarcinoma 
was found only in 1 patient. Lymphovascular invasion (LVI) 
was identified in 11.4% and there was no perineural invasion 
Fig. 1. Definition of primary tumor location. Coronal T2-weighted 
magnetic resonance image. Dashed line is the virtual line: a 
convergent level between rectal wall and levator ani muscle.
Table 1. Patient and tumor characteristics
Characteristic No. (%)
Follow-up duration (mo), median (range)
Age (yr), median (range)
Sex 
Male
Female
Preop CEA (ng/mL), median (range) 
POD7 CEA (ng/mL), median (range)
Operation 
LAR
Miles operation
Hartmann’s operation
Tumor size (cm), median (range)
Distal RM (cm), median (range)
Proximal RM (cm), median (range) 
Circumferential RM (cm), median (range)
Histology
Adenocarcinoma, well differentiated
Adenocarcinoma, moderately differen-
tiated
Adenocarcinoma, poorly differentiated
Mucinous
LVI
Positive
Negative
PNI
Positive
Negative
66.4 (1.4–126.1)
65 (27–81)
20 (57.1)
15 (42.9)
2.8 (0.0–35.0)
1.3 (0.0–11.9)
22 (62.9)
12 (34.3)
1 (2.9)
5.0 (2.5–9.0)
1.5 (0.1–15.0)
12.0 (2.5–30.0)
0.6 (0.1–1.3)
3 (8.6)
30 (85.7)
1 (2.9)
1 (2.9)
4 (11.4)
31 (88.6)
0 (0.0)
35 (100.0)
POD7, postoperative day 7; CEA, carcinoembryonic antigen; LAR, 
low anterior resection; RM, resection margin; LVI, lymphovascular 
invasion; PNI, perineural invasion.
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(PNI). Most of the patients had favorable histologic features. 
2. Patterns of recurrence
Eight (22.9%) of the 35 patients developed recurrences (Table 
2). Three (8.6%) was LR only, 3 (8.6%) was DM only, and 2 
(5.7%) was LR with DM. The mean time to recurrence was 89.9 
months. All LR was located at primary tumor sites (Fig. 2). DMs 
were observed in lung (3 patients), liver (1 patient), and para-
Table 2. Recurrences
Pattern of recurrences No. (%)
Local recurrence
Distant metastasis
Local recurrence + distant metastasis
Total
3 (8.6)
3 (8.6)
2 (5.7)
8 (22.9)
Fig. 2. Location of local recurrence. Computed tomography or T2-weighted magnetic resonance images of 5 patients who had local 
recurrence. Left 2 images of each patient show primary rectal cancer (white arrow, 1A, 1B, 2A, 2B, 3A, 3B, 4A, 4B, 5A, and 5B) in the lower 
rectum. Right 2 images of each patient show recurrent rectal cancer at primary tumor site (white arrow head, 1C, 1D, 2C, 2D, 3C, 3D, 4C, 4D, 
5C, and 5D).
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aortic lymph node (1 patient).
3. Risk factors and survival 
For risk factor analysis, tumor differentiation, LVI, PNI, 
preoperative CEA, postoperative CEA, tumor size, and RMs 
(distal, proximal, circumferential) were evaluated (Table 3). 
There was no LR from tumors smaller than 5 cm. Tumors 
over 5 cm tend to be related with LR. However, it was not 
statistically significant (p = 0.065). Although there was no 
statistical significance, all LRs were developed from the 
tumors with circumferential resection margins less than 
0.6 cm. Poorly differentiated adenocarcinoma seemed to be 
related with DM (p = 0.021), but there was only 1 patient 
with poorly differentiated adenocarcinoma and this patient 
had DM. Therefore, we did not interpret that there was a true 
relationship between poorly differentiated adenocarcinoma 
and DM. The methods of operation were not associated with 
LR. There was no other risk factor for LR. Among 3 patients 
with LR, 2 patients died despite salvage treatment and 1 
patient was alive with disease after salvage CRT. The overall 
survival rate, local control rate, and DM-free survival rate at 5 
years was 79.8%, 83%, and 87%, respectively.
Discussion and Conclusion
The aim of this study was not to find out the role of postope-
rative RT in lower rectal cancer. In this study we wanted to 
find out the possibility of modification of the postoperative RT 
target volume through evaluation of the patterns of LRR to 
reduce RT-induced toxicities. 
Since the introduction of TME, LR rates have been reduced 
significantly. The intermediate risk group for rectal cancer 
(pathologic T3N0, T1/2N1) has a favorable outcome. The 
necessity of RT for patients with intermediate risk of rectal 
cancer is controversial. Gunderson et al. [7] suggested that 
postoperative CRT for all patients with intermediate risk 
of rectal cancer may be excessive. In rectal cancer pooled 
analysis, there was no statistically significant difference in 
local failure between patients with surgery plus chemotherapy 
and with surgery plus CRT [8]. Park et al. [9] evaluated the 
effect of postoperative RT on LR in stage IIa rectal cancer. 
They analyzed 390 patients with stage IIa rectal cancer treated 
with TME plus chemotherapy or CRT. The LR rate was very 
low (2.8%). RT had no effect on LR and LR-free survival rate. 
Frasson et al. [10] analyzed the LR, disease-free survival, and 
cancer specific survival for the patients who had cT3N0/+ or 
cT2N+ rectal cancer and were not treated with preoperative 
CRT. They reported the LR rate was 5.4% in the patients with 
preoperative free CRM (free margin >2 mm from mesorectal 
fascia) after TME alone. For these patients, they suggested 
TME alone to avoid overtreatment. However, the current 
standard of treatment for intermediate risk of rectal cancer 
Table 3. Risk factors for 5-year LRFS, DMFS, and RFS
Risk factor
p-value
5-yr LRFS 5-yr DMFS 5-yr RFS
Tumor differentiation
Well differentiated
Moderately differentiated
Poorly differentiated
Mucinous
LVI (+) vs. (-)
PNI (+) vs. (-)
Preoperative CEA (≥2.8 vs. <2.8)
POD7 CEA (≥1.3 vs. <1.3)
Tumor size (≥5 vs. <5)
Distal RM (≥1.5 vs. <1.5)
Proximal RM (≥12.0 vs. <12.0)
Lateral RM (≥0.6 vs. <0.6)
0.329
0.530
-
0.689
0.229
-
0.830
0.226
0.065
0.105
0.621
0.362
0.488
0.712
0.021
0.700
0.488
-
0.999
0.267
0.718
0.548
0.351
0.532
0.776
0.362
0.000
0.569
0.303
-
0.909
0.880
0.365
0.548
0.965
0.830
LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival; RFS, recurrence-free survival; LVI, lymphovascular 
invasion; PNI, perineural invasion; CEA, carcinoembryonic antigen; POD7, postoperative day 7; RM, resection margin.
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is preoperative CCRT followed by surgery. According to the 
NCCN guidelines, when pT3N0 rectal cancer is diagnosed after 
upfront surgery, postoperative CCRT is recommended except in 
proximal rectal cancer with favorable pathologic features. We 
did not focus on the role of postoperative RT in pT3N0 rectal 
cancer. Even though the rate of LRR is low, we evaluated the 
patterns of LRR to find out the potential of modification of 
the postoperative RT target volume for reducing RT-induced 
toxicities. We found that most of the LRR occurred at the 
primary tumor site. 
The main reason for the controversy about postoperative RT 
is RT-induced toxicity. Dahlberg et al. [11] studied the functional 
result after RT with the patients in the Swedish Rectal Cancer 
trial. They had the patients fill out a questionnaire. Median 
bowel frequency per week was higher in the irradiated group 
than the surgery-alone group (p < 0.001). Incontinence for 
loose stools (p < 0.001), urgency (p < 0.001), and emptying 
difficulties (p < 0.05) were all more common in the irradiated 
group. 
RT-induced complications in the patients who were included 
in a large study for comparing preoperative RT plus TME, and 
TME alone were also reported. Marijnen et al. [12] reported 
the acute perineal complications were slightly increased in 
the patients who received APR. Peeters et al. [6] reported late 
bowel dysfunction and sexual dysfunction increased in the 
patients with preoperative RT plus TME than TME alone. 
Recently, Wang et al. [13] reported the results of conventional 
RT-induced complications. In their study, incidence of grade 
3 lower digestive tract toxicities was 30.8% and grade 3 
urinary toxicities occurred in 2.1% of patients at 6 weeks after 
completion of RT. Late complications developed in 19.1% of 
patients (grade 1/2 lower digestive tract toxicities, 17 %; grade 
1/2 urinary toxicities, 2.1%). 
In a systemic review and meta-analysis of the impact of 
preo perative RT on long-term functional outcome, the majority 
of studies reported higher rates of anorectal dysfunction such 
as fecal incontinence, more bowel movements, higher rate of 
pad wearing, and urgency after preoperative RT [14]. 
Therefore, studies have been undertaken to reduce RT-
induced toxicity and to modify the RT field. Nijkamp et al. 
[15] analyzed the locations of LR in the 94 patients included 
in the Dutch TME trial using the three-dimensional model. In 
their study, most of the LRs were located at the lower two-
thirds of the pelvis. Also, patients without primary nodal 
involvement and a negative CRM had LR caudal to the S2-
S3 interspace. Thus, they suggested that the cranial border of 
the clinical target volume (CTV) could safely be lowered for 
patients without primary nodal or CRM involvement. If the 
cranial border of the CTV is lowered to S2-S3 interspace, the 
absolute small bowel exposure can be reduced over 60% with 
three-field conventional RT and 80% with Intensity-modulated 
radiation therapy.
Syk et al. [16] reported the location of recurrence was related 
with initial tumor height. Fifty-nine percent of recurrence 
in patients with the middle and high primary tumor (>5 cm 
from the anal verge, upper two-thirds of the rectum) was 
seen in the anastomotic site. Recurrences in patients with 
the lower primary tumor mostly developed in the lower one-
third of the pelvis and were distributed equally to anastomotic 
site, pre-sacral area, and pelvic side wall. They suggested the 
lowering of the upper limit of the CTV from 1.5 cm above the 
promontory to 3.5 cm below the promontory. In their study, LR 
was in the lower three-fourths of the pelvis for all patients. In 
this study, using radiologic findings, we defined the locations 
of tumors according to the VL and compared the locations 
of recurrences. The LRs in patients with lower tumors were 
located at the primary tumor site.
In EORTC 22921 trial [17], the RT field was limited the 
mesorectum below to the S2-S3 interspace. The RT field 
included 5 cm above and 5 cm below the tumor in longitudinal 
axis, and extended 3 cm anterior and lateral to the tumor. 
However, this limited volume is consistent with local control 
those were reported in previous studies.
Most of these studies investigated the modification of RT 
target volume with the patients who received preoperative 
CCRT or preoperative short course RT. We evaluated the 
locations of local failure in the patients with favorable 
pathologic features who received surgery first. All LR occurred 
at the primary tumor location. We suggest that a smaller RT 
field can be applied to pT3N0 lower rectal cancer patients to 
reduce the RT-induced toxicities. 
There were limitations for statistical analyzing the relation-
ship between LR and the risk factors such as tumor size, me-
thods of operation and RM since this study was a retrospective 
study with small patients and there were only 5 LR. This 
study could not reflect the entire T3N0 rectal cancer patients. 
The patients included in this study had favorable pathologic 
features. There is a selection bias because receiving surgery 
first was determined by surgeons dependent on the clinical 
stage. Since the T3N0 group is very heterogeneous, the ESMO 
guidelines recommend risk-adapted treatment using the TNM 
classification with sub-classifications regarding the depth of 
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perirectal tissue invasion. We tried to collect the information 
of perirectal tissue invasion. However, because 20% (7 
patients) of patients preoperatively underwent CT without MRI, 
the depth of perirectal tissue invasion could not be considered. 
In this study, we defined the lower rectal cancer as the tumor 
with the invasion below the convergent level of levator ani 
muscle and rectal wall. So, even though the tumor located in 
the lower rectum and was pathologically T3, appropriate RM 
could be achieved with anal preserving surgery in most cases. 
There were 3 patients who had tumor near the anal canal with 
internal sphincter invasion. They received Miles’ operation. 
The recurrence rate could be underestimated, since this 
study was retrospective and short follow-up duration. Even 
though the patients who were included in this study had 
pathologically favorable pT3N0 rectal cancer, LR developed 
in 14.3% of patients. Most of the LR was located at primary 
tumor sites prior to surgery. Based on these findings, it 
might seem reasonable to consider postoperative RT with a 
smaller radiation field to primary tumor sites rather than the 
conventional whole pelvic irradiation.
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